A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.

@article{Florescu2008ACP,
  title={A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.},
  author={Marie Florescu and B. B. Eldin Hasan and Lesley Seymour and Keyue Ding and Frances A. Shepherd},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2008},
  volume={3 6},
  pages={590-8}
}
INTRODUCTION BR.21 demonstrated significant survival benefit for non-small cell lung cancer patients receiving erlotinib compared with placebo. We undertook to characterize, by exploratory subset analysis, patients less likely to benefit from erlotinib. METHODS Using stratification and potential prognostic factors, Cox regression with stepwise selection with minimum Akaike Information Criteria was used to separate erlotinib patients into risk categories based on 10th, 50th, and 90th… CONTINUE READING